Special Issues

Faculty Perspectives: Preventing and Managing Skeletal-Related Events in Cancer Patients with Bone Metastases and Multiple Myeloma

Best Practices in Genitourinary Oncology Navigation: Renal-Cell Carcinoma – July 2021

March 2021 Clinical Trials to Clinical Practice

TON - Evolving Guidelines
Epithelial ovarian cancer is the fifth leading cause of cancer mortality in women and is the leading cause of death due to gynecologic cancer in the United States. Read More ›

June 2020 Clinical Trials to Clinical Practice

Faculty Perspectives: PI3K Inhibitors: Efficacy in Hematologic Malignancies and Management of Treatment-Related Adverse Events - TON

Faculty Perspectives: Considerations in Metastatic Colorectal Cancer: Practical Applications and Patient Management for Oncology Nurses and Pharmacists

There have been significant improvements in the survival of patients with metastatic colorectal cancer (mCRC) over the past decade. However, patients with the disease who fail to respond to first- or second-line therapies, including chemotherapy and monoclonal antibodies, have few treatment options. Advances in subsequent treatment lines rather than in first- or second-line therapies now drive improvements in survival for these patients.

Read More ›

Best Practices in Patient Navigation – Navigating Hematologic Malignancies

Faculty Perspectives: Next-Generation Sequencing Testing in Oncology || Part 4 of a 4-Part Series
Following the advent of molecularly targeted agents, and more recently, immunotherapy, over the past few decades, we have witnessed dramatic changes in the treatment paradigms for many types of cancer. These advancements were driven by molecular profiling that enabled the identification of those patient populations most likely to benefit from targeted therapy and/or immunotherapy—that is, precision medicine. Read More ›

Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series
There is renewed interest in MSI analysis because the MSI-H/dMMR phenotype has emerged as an actionable predictive biomarker for immune checkpoint blockade therapy in different cancer types. This review presents available evidence supporting the clinical relevance and predictive value of MSI/dMMR in cancers, including those treated with immune checkpoint inhibitors (ICIs), and outlines the diagnostic approaches developed to assess MSI/dMMR in clinical practice. Read More ›

Page 1 of 5


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: